Dermatologic toxicities in epidermal growth factor receptor and multikinase inhibitors

J Adv Pract Oncol. 2012 May;3(3):138-50. doi: 10.6004/jadpro.2012.3.3.2.

Abstract

Targeted therapies have produced significant treatment advances for patients diagnosed with a variety of tumor types. These therapies are associated with unique dermatologic toxicities that may hamper treatment efforts and cause significant discomfort for patients. Prevention and management of these toxicities can allow patients to remain on therapy and hence receive maximum clinical benefit from the drug.

Publication types

  • Review